Related papers: Optimized Treatment Schedules for Chronic Myeloid …
Phase Ib/II oncology trials, despite their small sample sizes, aim to provide information for optimal internal company decision-making concerning novel drug development. Hybrid controls (a combination of the current control arm and controls…
Personalizing combination therapies in oncology requires navigating an immense space of possible drug and dose combinations, a task that remains largely infeasible through exhaustive experimentation. Recent developments in patient-derived…
Individualized treatment rules/recommendations (ITRs) aim to improve patient outcomes by tailoring treatments to the characteristics of each individual. However, when there are many treatment groups, existing methods face significant…
The dynamic environment of laboratories and clinics, with streams of data arriving on a daily basis, requires regular updates of trained machine learning models for consistent performance. Continual learning is supposed to help train models…
Precision medicine has led to a paradigm shift allowing the development of targeted drugs that are agnostic to the tumor location. In this context, basket trials aim to identify which tumor types - or baskets - would benefit from the…
Periodic hematological diseases such as cyclical neutropenia or cyclical thrombocytopenia, with their characteristic oscillations of circulating neutrophils or platelets, may pose grave problems for patients. Likewise, periodically…
The recent increase in morbidity is primarily due to chronic diseases including Diabetes, Heart disease, Lung cancer, and brain tumours. The results for patients can be improved, and the financial burden on the healthcare system can be…
We consider a real-world chemotherapy scheduling template design problem, where we cluster patient types into groups and find a representative time-slot duration for each group to accommodate all patient types assigned to that group, aiming…
The majority of cancer-related fatalities are due to metastatic disease. In chemoradiotherapy, chemotherapeutic agents are administered along with radiation to increase damage to the primary tumor and control systemic disease such as…
Phase I-II cancer clinical trial designs are intended to accelerate drug development. In cases where efficacy cannot be ascertained in a short period of time, it is common to divide the study in two stages: i) a first stage in which dose is…
Combination drug therapies hold significant promise for enhancing treatment efficacy, particularly in fields such as oncology, immunotherapy, and infectious diseases. However, designing clinical trials for these regimens poses unique…
A distributed optimal control problem for a diffuse interface model, which physical context is that of tumour growth dynamics, is addressed. The system we deal with comprises a Cahn--Hilliard equation for the tumour fraction coupled with a…
Prostate cancer can be lethal in advanced stages, for which chemotherapy may become the only viable therapeutic option. While there is no clear clinical management strategy fitting all patients, cytotoxic chemotherapy with docetaxel is…
Dynamic treatment regimes (DTRs) are used in medicine to tailor sequential treatment decisions to patients by considering patient heterogeneity. Common methods for learning optimal DTRs, however, have shortcomings: they are typically based…
Heterogeneous treatment effect estimation is critical in oncology, particularly in multi-arm trials with overlapping therapeutic components and long-term survivors. These shared mechanisms pose a central challenge to identifying causal…
In this article, we focus on determining a minimum-cost treatment program aimed at maintaining the size of a cancerous tumor at a level that allows the patient to live comfortably. At each predetermined point in a treatment horizon, the…
We mathematically justify metronomic chemotherapy as the best strategy to apply most cytotoxic drugs in oncology for both curative and palliative approaches, assuming the classical pharmacokinetic model together with the Emax…
Multidrug resistance consists of a series of genetic and epigenetic alternations that involve multifactorial and complex processes, which are a challenge to successful cancer treatments. Accompanied by advances in biotechnology and…
Various approaches to increase efficiency of antitumor therapy by a combination of vaccinotherapy, chemotherapy and surgical excision of primary tumor nodes, and also the comparative analyses of therapeutic and preventive application of…
In this work, we aim to predict the survival time (ST) of glioblastoma (GBM) patients undergoing different treatments based on preoperative magnetic resonance (MR) scans. The personalized and precise treatment planning can be achieved by…